GO
Loading...

Dyax Says Genetic Disease Drug Meets Goals; Shares Surge

Reuters
Thursday, 12 Apr 2007 | 5:22 PM ET

Dyax said its product candidate for hereditary angioedema, a genetic disease, met its main goal in a late-stage trial, sending the biopharmaceutical company's shares up more than 40% in after-hours trading.

The drug, codenamed DX-88, achieved statistically significant results for both the primary and secondary endpoints, Dyax said in a statement.

Hereditary angioedema is characterized by episodes of acute swelling and inflammation.

The company said the overall safety results showed that the drug continues to be well tolerated.

Dyax said it will present more detailed results next week.

Shares of the company rose to $5.87 in late electronic trading, after closing at $4.00 Thursday on the Nasdaq.

  Price   Change %Change
DYAX
---

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.

  • In this excerpt from a live CNBC interview, Warren Buffett explains why it's extremely unusual for a company's directors to vote against executive compensation plans.

  • Mad Money host Jim Cramer says shareholder activism works for every shareholder, and offers his take on the Valeant/Bill Ackman bid to acquire Allergan. The market is better off for these efforts, he says.